Search Results - "Mocikat, Ralph"

The role of dendritic cells for therapy of B-cell lymphoma with immune checkpoint inhibitors by Scheuerpflug, Anne, Ahmetlić, Fatima, Bauer, Vera, Riedel, Tanja, Röcken, Martin, Mocikat, Ralph

“…Immune checkpoint blocking (ICB) is a promising new tool of cancer treatment. Yet, the underlying therapeutic mechanisms are not fully understood. Here we…”
Get full text

EBV-gp350 confers B-cell tropism to tailored exosomes and is a neo-antigen in normal and malignant B cells--a new option for the treatment of B-CLL by Ruiss, Romana, Jochum, Simon, Mocikat, Ralph, Hammerschmidt, Wolfgang, Zeidler, Reinhard

“…gp350, the major envelope protein of Epstein-Barr-Virus, confers B-cell tropism to the virus by interacting with the B lineage marker CD21. Here we utilize…”
Get full text

Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody by Stangl, Stefan, Gehrmann, Mathias, Riegger, Julia, Kuhs, Kristin, Riederer, Isabelle, Sievert, Wolfgang, Hube, Kathrin, Mocikat, Ralph, Dressel, Ralf, Kremmer, Elisabeth, Pockley, Alan G., Friedrich, Lars, Vigh, Laszlo, Skerra, Arne, Multhoff, Gabriele, Kondorosi, Eva

“…Immunization of mice with a 14-mer peptide TKDNNLLGRFELSG, termed "TKD," comprising amino acids 450–461 (aa 450–461 ) in the C terminus of inducible Hsp70,…”
Get full text

Immune checkpoint blockade impairs immunosuppressive mechanisms of regulatory T cells in B-cell lymphoma by Bauer, Vera, Ahmetlić, Fatima, Hömberg, Nadine, Geishauser, Albert, Röcken, Martin, Mocikat, Ralph

“…•During lymphoma growth, Tregs evolve an increasingly suppressive phenotype.•Lymphoma-infiltrating Tregs show an enhanced immunosuppressive function.•Cell…”
Get full text

Therapy of lymphoma by immune checkpoint inhibitors: the role of T cells, NK cells and cytokine-induced tumor senescence by Ahmetlic, Fatima, Fauser, Josia, Riedel, Tanja, Bauer, Vera, Flessner, Carolin, Hömberg, Nadine, Hennel, Roman, Brenner, Ellen, Lauber, Kirsten, Röcken, Martin, Mocikat, Ralph

“…BackgroundAlthough antibodies blocking immune checkpoints have already been approved for clinical cancer treatment, the mechanisms involved are not yet…”
Get full text

EpCAM, a human tumor-associated antigen promotes Th2 development and tumor immune evasion by Ziegler, Alexandra, Heidenreich, Regina, Braum¨ller, Heidi, Wolburg, Hartwig, Weidemann, Susanne, Mocikat, Ralph, Röcken, Martin

“…Experimental tumor vaccination and adoptive T-cell therapies show that interferon-γ (IFN-γ)–producing CD4+ T helper cells (Th1) can be highly effective in…”
Get full text

837 Interleukin-10 drives the development of T regulatory type 1 (Tr1) cells and is a target for immunotherapy by Ma, Yanchun, Bauer, Vera, Riedel, Tanja, Hofer, Thomas, Roecken, Martin, Mocikat, Ralph

“…BackgroundIn recent years, immunotherapy has become a common tool of cancer treatment. In order to define therapeutic targets, it is necessary to understand…”
Get full text

A novel CXCL10-based GPI-anchored fusion protein as adjuvant in NK-based tumor therapy by Muenchmeier, Niklas, Boecker, Sophia, Bankel, Lorenz, Hinz, Laura, Rieth, Nicole, Lapa, Constantin, Mendler, Anna N, Noessner, Elfriede, Mocikat, Ralph, Nelson, Peter J

“…Cellular therapy is a promising therapeutic strategy for malignant diseases. The efficacy of this therapy can be limited by poor infiltration of the tumor by…”
Get full text

Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy by Eissler, Nina, Mysliwietz, Josef, Deppisch, Nina, Ruf, Peter, Lindhofer, Horst, Mocikat, Ralph

“…Trifunctional bispecific antibodies (trAbs) used in tumor immunotherapy have the unique ability to recruit T cells toward antigens on the tumor cell surface…”
Get full text

Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model by Ruf, Peter, Schäfer, Beatrix, Eissler, Nina, Mocikat, Ralph, Hess, Juergen, Plöscher, Matthias, Wosch, Susanne, Suckstorff, Ivonne, Zehetmeier, Christine, Lindhofer, Horst

“…Trifunctional bispecific antibodies (trAb) are a special class of bispecific molecules recruiting and activating T cells and accessory immune cells…”
Get full text

In memoriam: Stefan Thierfelder by Kolb, Hans-Jochem, Ph.D., M.D, Mocikat, Ralph, Ph.D., M.D, Kremmer, Elisabeth, M.D

Get full text

Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine by Adam, Christian, Mysliwietz, Josef, Mocikat, Ralph

“…Dendritic cells (DC) pulsed with tumor-derived antigenic material have widely been used in antitumor vaccination protocols. However, the optimal strategy of DC…”
Get full text

T-helper-1-cell cytokines drive cancer into senescence by Braumüller, Heidi, Wieder, Thomas, Brenner, Ellen, Aßmann, Sonja, Hahn, Matthias, Alkhaled, Mohammed, Schilbach, Karin, Essmann, Frank, Kneilling, Manfred, Griessinger, Christoph, Ranta, Felicia, Ullrich, Susanne, Mocikat, Ralph, Braungart, Kilian, Mehra, Tarun, Fehrenbacher, Birgit, Berdel, Julia, Niessner, Heike, Meier, Friedegund, van den Broek, Maries, Häring, Hans-Ulrich, Handgretinger, Rupert, Quintanilla-Martinez, Leticia, Fend, Falko, Pesic, Marina, Bauer, Jürgen, Zender, Lars, Schaller, Martin, Schulze-Osthoff, Klaus, Röcken, Martin

“…T-helper-1-cell cytokines tumour necrosis factor and interferon-γ are shown to drive tumour cells into senescence in a mouse model of β-cell carcinoma and…”
Get full text

Reversal of tumor acidosis by systemic buffering reactivates NK cells to express IFN‐γ and induces NK cell‐dependent lymphoma control without other immunotherapies by Pötzl, Johann, Roser, David, Bankel, Lorenz, Hömberg, Nadine, Geishauser, Albert, Brenner, Christoph D., Weigand, Michael, Röcken, Martin, Mocikat, Ralph

“…Like other immune cells, natural killer (NK) cells show impaired effector functions in the microenvironment of tumors, but little is known on the underlying…”
Get full text

Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours by Brenner, Ellen, Schörg, Barbara F., Ahmetlić, Fatima, Wieder, Thomas, Hilke, Franz Joachim, Simon, Nadine, Schroeder, Christopher, Demidov, German, Riedel, Tanja, Fehrenbacher, Birgit, Schaller, Martin, Forschner, Andrea, Eigentler, Thomas, Niessner, Heike, Sinnberg, Tobias, Böhm, Katharina S., Hömberg, Nadine, Braumüller, Heidi, Dauch, Daniel, Zwirner, Stefan, Zender, Lars, Sonanini, Dominik, Geishauser, Albert, Bauer, Jürgen, Eichner, Martin, Jarick, Katja J., Beilhack, Andreas, Biskup, Saskia, Döcker, Dennis, Schadendorf, Dirk, Quintanilla-Martinez, Leticia, Pichler, Bernd J., Kneilling, Manfred, Mocikat, Ralph, Röcken, Martin

“…Immune checkpoint blockade (ICB)-based or natural cancer immune responses largely eliminate tumours. Yet, they require additional mechanisms to arrest those…”
Get full text

Trifunctional Bispecific Antibodies Induce Tumor-Specific T Cells and Elicit a Vaccination Effect by EISSLER, Nina, RUF, Peter, MYSLIWIETZ, Josef, LINDHOFER, Horst, MOCIKAT, Ralph

“…A major goal of tumor immunotherapy is the induction of long-lasting systemic T-cell immunity. Bispecific antibodies (bsAbs) that lack the immunoglobulin Fc…”
Get full text

Interleukin-10 counteracts T-helper type 1 responses in B-cell lymphoma and is a target for tumor immunotherapy by Ma, Yanchun, Bauer, Vera, Riedel, Tanja, Ahmetlić, Fatima, Hömberg, Nadine, Hofer, Thomas P., Röcken, Martin, Mocikat, Ralph

“…To establish strategies for immunotherapy of B-cell lymphoma, it is mandatory to gain deeper insights into the mechanisms of tumor immune escape. In a mouse…”
Get full text

Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses by Mocikat, Ralph, Braumüller, Heidi, Gumy, Alain, Egeter, Oliver, Ziegler, Heike, Reusch, Uwe, Bubeck, Anja, Louis, Jacques, Mailhammer, Reinhard, Riethmüller, Gert, Koszinowski, Ulrich, Röcken, Martin

“…Conserved molecular patterns derived from pathogenic microorganisms prime antigen-presenting dendritic cells (DC) to induce adaptive T cell responses. In…”
Get full text

Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery by Deppisch, Nina, Ruf, Peter, Eissler, Nina, Neff, Frauke, Buhmann, Raymund, Lindhofer, Horst, Mocikat, Ralph

“…Trifunctional bispecific antibodies (trAb) are novel anticancer drugs that recruit and activate different types of immune effector cells at the targeted tumor…”
Get full text

779 Immune checkpoint blockade impacts the suppressive phenotype and function of regulatory T cells in an endogenous mouse lymphoma model by Bauer, Vera, Ahmetlic, Fatima, Roecken, Martin, Mocikat, Ralph

“…BackgroundAntibodies against programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have become established part of…”
Get full text